Onward Medical N.V.

As of June 30, 2026, Onward Med NV carries a market capitalization of 209.93M, placing it among publicly traded companies globally. Its enterprise value stands at 132.56M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Onward Med NV's next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2026, Onward Med NV has 69.53M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Onward Med NV maintains a current ratio of 9.23, meaning it holds 9.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 9, 2026, Onward Med NV's stock has declined approximately 53.44% over the past 52 weeks.

As of June 30, 2026, Onward Med NV holds 93.12M in cash and equivalents against 15.75M in total debt, resulting in a net debt position of -17.39M. Total book value stands at 82.19M, with working capital of 91.55M providing operational flexibility.